To further assess whether the ability of Nedd4 to positively regulate T cell development plays a role in MS pathogenesis, we first measured NEDD4, NEDD4-2, and RORγt protein expression in CD4+ T cells from 6 relapsing–remitting multiple sclerosis (RRMS) patients (treatment-naïve and in remission) and 6 age- and sex-matched healthy donors. This evidence concerns the gene NEDD4L and myeloid sarcoma.